All future quarterly dividends will be subject to quarterly financial review and board approval. , the Company announced that its subsidiary Pinnacle Biologics, Inc. enrolled the first group of patients in a randomized Phase 2 trial to evaluate photodynamic therapy with PHOTOFRINA for patients with epithelioid malignant pleural mesothelioma.
